122 related articles for article (PubMed ID: 2165265)
1. Causes of the urinary concentrating defect in mice with nephrogenic diabetes insipidus.
Valtin H; Coffey AK; O'Sullivan DJ; Homma S; Dousa TP
Physiol Bohemoslov; 1990; 39(1):103-11. PubMed ID: 2165265
[TBL] [Abstract][Full Text] [Related]
2. High activity of low-Michaelis-Menten constant 3', 5'-cyclic adenosine monophosphate-phosphodiesterase isozymes in renal inner medulla of mice with hereditary nephrogenic diabetes insipidus.
Takeda S; Lin CT; Morgano PG; McIntyre SJ; Dousa TP
Endocrinology; 1991 Jul; 129(1):287-94. PubMed ID: 1647298
[TBL] [Abstract][Full Text] [Related]
3. Induction of intramembranous particle clusters in mice with nephrogenic diabetes insipidus.
Coffey AK; O'Sullivan DJ; Homma S; Dousa TP; Valtin H
Am J Physiol; 1991 Oct; 261(4 Pt 2):F640-6. PubMed ID: 1656782
[TBL] [Abstract][Full Text] [Related]
4. Cellular action of antidiuretic hormone in mice with inherited vasopressin-resistant urinary concentrating defects.
Dousa TP; Valtin H
J Clin Invest; 1974 Sep; 54(3):753-62. PubMed ID: 4368480
[TBL] [Abstract][Full Text] [Related]
5. Cellular action of vasopressin in medullary tubules of mice with hereditary nephrogenic diabetes insipidus.
Jackson BA; Edwards RM; Valtin H; Dousa TP
J Clin Invest; 1980 Jul; 66(1):110-22. PubMed ID: 6249843
[TBL] [Abstract][Full Text] [Related]
6. Role of cAMP-phosphodiesterase isozymes in pathogenesis of murine nephrogenic diabetes insipidus.
Homma S; Gapstur SM; Coffey A; Valtin H; Dousa TP
Am J Physiol; 1991 Aug; 261(2 Pt 2):F345-53. PubMed ID: 1652209
[TBL] [Abstract][Full Text] [Related]
7. The clinical physiology of water metabolism. Part II: Renal mechanisms for urinary concentration; diabetes insipidus.
Weitzman RE; Kleeman CR
West J Med; 1979 Dec; 131(6):486-515. PubMed ID: 545867
[TBL] [Abstract][Full Text] [Related]
8. The mechanism of urinary concentration in nephrogenic diabetes insipidus.
McConnell RF; Lorentz WB; Berger M; Smith EH; Carvajal HF; Travis LB
Pediatr Res; 1977 Jan; 11(1 Pt 1):33-6. PubMed ID: 188007
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
[TBL] [Abstract][Full Text] [Related]
10. Effects of rolipram and cilostamide on renal functions and cyclic AMP release in anesthetized dogs.
Tanahashi M; Hara S; Yoshida M; Suzuki-Kusaba M; Hisa H; Satoh S
J Pharmacol Exp Ther; 1999 Jun; 289(3):1533-8. PubMed ID: 10336549
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
12. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
13. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts.
Marko D; Romanakis K; Zankl H; Fürstenberger G; Steinbauer B; Eisenbrand G
Cell Biochem Biophys; 1998; 28(2-3):75-101. PubMed ID: 9515161
[TBL] [Abstract][Full Text] [Related]
14. Distinct profiles of phosphodiesterase isozymes in cultured cells derived from nonpigmented and pigmented ocular ciliary epithelium.
Bode DC; Hamel LT; Wax MB
J Pharmacol Exp Ther; 1993 Dec; 267(3):1286-91. PubMed ID: 8263791
[TBL] [Abstract][Full Text] [Related]
15. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
[TBL] [Abstract][Full Text] [Related]
16. Oocyte maturation involves compartmentalization and opposing changes of cAMP levels in follicular somatic and germ cells: studies using selective phosphodiesterase inhibitors.
Tsafriri A; Chun SY; Zhang R; Hsueh AJ; Conti M
Dev Biol; 1996 Sep; 178(2):393-402. PubMed ID: 8812137
[TBL] [Abstract][Full Text] [Related]
17. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
Barnette MS; Manning CD; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069
[TBL] [Abstract][Full Text] [Related]
18. Vasopressin-resistant nephrogenic diabetes insipidus. A result of amphotericin B therapy.
Barbour GL; Straub KD; O'Neal BL; Leatherman JW
Arch Intern Med; 1979 Jan; 139(1):86-8. PubMed ID: 760689
[TBL] [Abstract][Full Text] [Related]
19. Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions.
Lugnier C; Muller B; Le Bec A; Beaudry C; Rousseau E
J Pharmacol Exp Ther; 1993 Jun; 265(3):1142-51. PubMed ID: 8389853
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
